Somewhere between month four and month twelve, the scale stops moving. The medication hasn't changed, you haven't changed what you're doing, and the number that dropped steadily for months just sits there for three weeks straight.
This is the point where a lot of people decide the treatment stopped working and quit. That is almost always the wrong read. A plateau on GLP-1 therapy is a predictable, well-documented part of the curve — and what you do at the plateau matters more than the plateau itself.
Yes, and it shows up in the trial data as clearly as it shows up in clinic. In STEP 1 — the 68-week trial of semaglutide 2.4 mg in 1,961 adults with overweight or obesity — weight loss began at the first post-randomization check at week 4 and continued until it reached its lowest point at week 60. The curve flattened, and it flattened while participants were still taking the full dose.
The average result at week 68 was a 14.9% reduction in body weight, compared with 2.4% on placebo. So the plateau in that trial arrived *after* the large majority of the weight had already come off — not instead of it.
That timeline is worth holding onto. If you're plateauing around the one-year mark near your maximum dose, you are following the same curve the research describes. If you're plateauing at month three, something different is going on, and that distinction is the whole point of the next section.
Before treating a plateau as a plateau, check the dose. GLP-1 medications are started low and increased in steps to limit side effects, and in STEP 1 the dose-escalation phase alone ran 16 weeks. A stall while you're still climbing toward the target dose is not a plateau — it's a stage of treatment that isn't finished.
Two other things get mistaken for plateaus:
This is why we track waist circumference and how clothes fit alongside weight. When the scale is flat and the waist is still going down, treatment is working and the measurement is just too crude to show it.
Because your body actively defends against weight loss, and it gets better at it as you lose. Two mechanisms do most of the work.
The first is reduced energy expenditure. A smaller body costs less to run. You burn fewer calories at rest and fewer during the same workout, so the deficit that produced steady loss at your starting weight is a smaller deficit — sometimes no deficit at all — at your current weight. Nothing went wrong; the arithmetic moved.
The second is counter-regulation. Appetite and satiety signalling adapt over time to push intake back up. GLP-1 medication works against this directly, which is why it produces results that diet alone rarely sustains — but it blunts the response rather than abolishing it.
There's also a quieter contributor: loss of lean mass. Weight lost through any method includes some muscle, and muscle is metabolically active tissue. Lose enough of it and you lower your own energy expenditure further, which tightens the plateau you're trying to escape.
The useful answer depends on which of the above is driving it, which is why the first step is a reassessment rather than a change. In practice, the levers that matter most:
This is the most consequential decision at a plateau, and the evidence on it is unusually direct. The STEP 1 trial extension followed participants after semaglutide was withdrawn, and they regained a large share of the weight they had lost, with cardiometabolic improvements moving back toward baseline alongside it.
Canada's clinical practice guidance reflects that finding. The 2025 update to the Canadian Adult Obesity Clinical Practice Guidelines states that pharmacotherapy for obesity management should be used long term, when effective, together with health-behaviour changes — specifically to avoid weight regain and the loss of the health benefits already achieved.
Read that in the context of a plateau and it reframes the whole question. A plateau does not mean the medication stopped working. Holding a weight you previously could not hold *is* the medication working. Obesity is managed as a chronic condition, and treatment that maintains a result is doing its job in the same way blood-pressure medication does when your readings are normal.
The realistic goal at a plateau is usually not to force the scale down again at any cost. It's to decide, with your clinician, whether to push for more loss or consolidate what you have — and to stay treated either way.
If you've stalled, book a review rather than changing anything on your own. We'll look at your current dose and where you are in titration, your weight trend against your waist measurement, your protein intake and activity, your full medication list for anything working against you, and your tolerance for continuing to escalate.
Sometimes the outcome is a dose change. Sometimes it's a different agent. Often it's a training and protein plan plus a decision to hold steady — which is a legitimate result, not a consolation prize.
You can see how our GLP-1 program are structured, or book an assessment and we'll work through it together.
How long does a weight-loss plateau usually last?
It varies, and the more useful question is what's driving it. A stall of two to three weeks is often normal fluctuation rather than a true plateau. A genuine plateau that holds for a month or more at a stable dose is worth a formal reassessment rather than waiting it out, because the levers that break it — dose, protein, resistance training, other medications — need to be identified before they can be used.
Does a plateau mean the medication stopped working?
No. Holding a weight you previously could not hold is the medication working. In the STEP 1 trial the weight curve flattened at week 60 while participants were still on the full dose, and stopping treatment in the trial extension led to substantial regain. A plateau is a change in the rate of loss, not a loss of effect.
Should I increase my dose if I hit a plateau?
Only as part of a clinical reassessment. If you haven't reached your target dose and side effects are manageable, completing titration is often the most direct option. If you're already at the maximum tolerated dose, escalating further isn't the answer, and the plan should shift to lean-mass protection, intake review, and a medication audit.
Can building muscle break a plateau?
It's the most under-used option available. Weight lost through any method includes some lean mass, and muscle is metabolically active, so losing it lowers your energy expenditure and tightens the plateau. Resistance training two to three times a week with adequate protein targets that mechanism directly, and it improves body composition even in weeks when the scale doesn't move.
Will I regain the weight if I stop the medication after plateauing?
The evidence points that way. The STEP 1 trial extension found participants regained a large share of their lost weight after semaglutide was withdrawn, with cardiometabolic improvements reverting alongside. Canada's 2025 pharmacotherapy guideline update recommends obesity medication be used long term when it's effective, specifically to prevent that regain.
*Medically reviewed by Wessam Sakr, BScPharm. This article is general information, not medical advice for your specific situation. Talk to a healthcare professional about what's right for you.*
Ready to talk to a professional? Book a consultation with our pharmacist-led team to find the right medically supervised approach for you.